© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Dolutegravir Sodium stands as a widely recognized antiretroviral compound, mostly used in the treatment of HIV infection. Market use of dolutegravir sodium highlights its value as an integrase inhibitor, disrupting the viral replication process. For years, the healthcare sector has depended on this active pharmaceutical ingredient (API) to support effective combination therapies, lowering viral load in patients and improving quality of life across many communities. Chemists and pharmaceutical companies trust dolutegravir sodium for its stable synthetic route, well-characterized impurity profile, and established track record in clinical settings.
This compound appears either as a white to off-white solid or as slightly yellowish flakes, depending on batch source and purity level. Its structure features a molecular weight of about 441.367 grams per mole. The chemical formula reads C20H18F2N3NaO5. As a solid, dolutegravir sodium typically comes in crystalline powder or small pearlescent shards, often with a density close to 1.7 g/cm³ based on published data. Its crystal lattice shows tight packing, offering a high melting point, usually near 288°C, a feature that translates well for stable storage and process applications. Solubility testing shows sparing dissolution in pure water, with greater solubility in some organic solvents, which creates consideration for formulation specialists focused on improving bioavailability in tablet production or oral solutions.
Dolutegravir sodium includes two fluorine atoms on the aromatic ring, contributing to its improved potency and metabolic stability. The carboxamide group at the terminus increases its affinity for the integrase enzyme, providing a robust mechanism of action. Chemists working with this API often reference its sodium salt form to enhance both its solubility and physical handling versus the base structure. Its three-ring fused backbone, plus the relative flatness of the molecule, streamlines method development for quality control—high-performance liquid chromatography (HPLC) and ultraviolet detection both pick up its distinct spectral signature.
Pharmaceutical applications demand a high level of purity, typically above 98% on a dry basis. The raw material often arrives as microcrystalline powder, which supports consistent blending and tablet compression. For researchers, small-scale samples may present as flakes or semi-lustrous pearls, but both flake and power forms maintain the same activity and reactivity profile in aqueous and non-aqueous solutions. Analytical chemists flag certain specifications: water content, residual solvents, heavy metal traces, and particle size distribution, all critical to meet international regulatory standards.
Global supply chains recognize this material by its harmonized system (HS) code, usually falling under "2933.59.95," the category for heterocyclic compounds with nitrogen atoms. As import and export regulations grow tighter for APIs, correct HS code declaration eases the cross-border movement of dolutegravir sodium and supports transparent customs documentation. Companies keep extensive paperwork not only for customs but also for traceability, quality assurance, and recall preparedness—lessons learned from past incidents with subpar raw materials in the industry.
Manufacturing facilities treat dolutegravir sodium as a low-to-moderate hazard chemical. Direct exposure risks remain minimal, yet standard good laboratory practices remain non-negotiable. Operators must wear gloves and masks to avoid respiratory or dermal irritation, and labs always use local exhaust ventilation. Spillage concerns focus more on environmental control, since active pharmaceutical residues can interfere with water ecosystems. Production lines undertake waste management, using incineration or designated chemical disposal systems to prevent bioactive contamination.
Raw materials like dolutegravir sodium signify more than just a step in manufacturing. Consistency in particle size, correct salt form, and impurity content all influence final drug safety. A few years ago, several recalls in the pharmaceutical industry stemmed from adulterated APIs, underscoring the need for global suppliers to adopt full traceability, robust third-party audits, and frequent batch testing using both compendial and advanced chromatographic methods. End-to-end transparency, from synthesis to packaging, stands as one pathway to protect patient welfare and avoid costly disruptions. Companies sometimes build direct relationships with primary manufacturers, reducing dependence on intermediaries and driving accountability back at the source. As drug development grows more complex, so does scrutiny on these starter chemicals.
Choosing and scrutinizing ingredients like dolutegravir sodium reflects more than technical chemistry. It means standing up for standards that impact vulnerable populations. Hospitals and clinics build trust in treatments through the unseen layers of quality assurance baked into every kilogram of API. Patients, often unaware of the journey their medicine takes, rely on that behind-the-scenes diligence. Stronger regulatory science, international exchange of best practices, and technological tools—such as real-time batch monitoring—will shape the future. For those in research, manufacturing, or regulatory roles, a better supply chain for dolutegravir sodium leads directly to healthier lives and greater confidence in medicine.
